September 6th, 2021
Protein Alternatives (ProAlt) was selected by the European Innovation Council Business Acceleration Services to present to Merck its therapeutic antibody PA-0661 in oncology. ProAlt will be one of the 16 selected companies from 10 different countries that will present innovative projects to Merck on September 30.

Merck, the multinational Healthcare, Life Science and Electronics company, is looking for SMEs ‘to share their love of science and passion for technology’.

This specially designed event aims at collaborating with Merck through dedicated pitching sessions and one-on-one business meetings.

Find out more at: